Smith & Nephew PLC (SNN) Stock AnalysisSNNSmith & Nephew PLC

Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Smith & Nephew PLC (SNN) is currently priced at $29.06, with a high RSI of 88.788 indicating it may be overbought. The forward P/E ratio is 11.16, suggesting it is relatively cheap compared to its earnings potential. However, hedge funds have increased selling by 225.80% over the last quarter, which raises a concern about future performance. Given these factors, it is advisable to hold rather than buy at this moment.

4 analysts cover SNN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 35.75.